Structure via PubChem · Public domain (PubChem)
abciximab
Sign in to saveAlso known as antiGPIIBIIIa, ReoPro, Reopro, Abciximac, c7E3, 7E3, C7E3, 7E3 antibody
Abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor.
Key facts
- Drug.KEGG
- D02778
- Drug.ChEMBL
- 1201584
- Drug.UNII
- X85G7936GV
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 477237058
- Drug.type
- mab
- Drug.image
- Abciximab.png
- Drug.mab_type
- Fab
- Drug.source
- xi/o
- Drug.target
- CD41 7E3
- Drug.tradename
- Reopro
- Drug.DailyMedID
- Abciximab
- Drug.licence_US
- Abciximab
- Drug.pregnancy_US
- C
- Drug.routes_of_administration
- Intravenous (IV)
- Drug.ATC_prefix
- B01
- Drug.ATC_suffix
- AC13
- Drug.legal_UK
- POM
via Wikipedia infobox
Chemical data
- Formula
- C22H27ClN4O3S
- Molecular weight
- 463 g/mol
- IUPAC name
- 4-[[2-[1-(4-chloro-2,5-dimethylphenyl)sulfonylpiperidin-4-yl]imidazol-1-yl]methyl]-3,5-dimethyl-1,2-oxazole
- SMILES
- CC1=CC(=C(C=C1Cl)C)S(=O)(=O)N2CCC(CC2)C3=NC=CN3CC4=C(ON=C4C)C
- InChIKey
- WXEDUKRNQGUVRZ-UHFFFAOYSA-N
- XLogP
- 3.6
- Polar surface area
- 89.6 Ų
- H-bond donors
- 0
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Research
2,802 papers- How abciximab might be clinically useful.International journal of cardiology · 2016
- [Abciximab].Nihon rinsho. Japanese journal of clinical medicine · 2006
- ABCIXIMAB: a new antiaggregant used in angioplasty.The Annals of pharmacotherapy · 1996
- Abciximab readministration.Reviews in cardiovascular medicine · 2002
- Abciximab as an adjunctive therapy for patients undergoing percutaneous coronary interventions.Expert opinion on biological therapy · 2011
via PubMed
Wikidata facts
- Mass
- 462.149239
- Official website
- www.abciximab.com
Show 4 more facts
- chemical formula
- C₂₂H₂₇ClN₄O₃S
- canonical SMILES
- CC1=CC(=C(C=C1Cl)C)S(=O)(=O)N2CCC(CC2)C3=NC=CN3CC4=C(ON=C4C)C
- defined daily dose
- 25
- Commons category
- Abciximab
via Wikidata · CC0
~3 min read
Article
5 sectionsContents
- Indications for use
- Pharmacokinetics
- Side-effects
- References
- External links
Abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor.
While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug. Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.